Genmab — November 2018
-
Svaret fra Rachel: "As you say, yesterday there was held a summary judgement hearing. However, nothing was decided at the hearing, the judge heard the arguments but has not yet given a ruling. With the regard to yesterday’s proceedings. We were pleased with the outcome of the court hearing. With one exception, the court denied all of MorpohoSys’s motions, including motions to exclude evidence from trial and for judgment on certain claims.
-
The only MorphoSys motion that was granted was simply entering judgment on infringement of certain patent claims that we had already stipulated to several months ago (under the court’s current claim construction to which we continue to disagree and to which we have the right to appeal), but to which we believe we have very strong invalidity defenses.
-
In contrast, the court did not rule on Janssen and Genmab’s motions to invalidate the asserted patents, and a decision would be expected in the next two months. Should the case be halted for any reason we would, as covered by our disclosure obligations, issue a company announcement concerning the outcome. Otherwise, the case would continue as planned to a jury trail in February next year."
-
DaraPomD in AL amyloidosis -abstract
https://journals.sagepub.com/doi/full/10.1177/1078155218815305 -
-
Er der nogle der ved om der er søgt RTOR?
-
Obs. Zealand Pharma Q&A starter kl. 15.
-
small new trial Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma (IDARA) https://clinicaltrials.gov/ct2/show/NCT03757221?term=NCT03757221&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind